You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxprenolol
Accession NumberDB01580
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. [PubChem]
Structure
Thumb
Synonyms
Oxprenolol
Oxprenololum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Slow Trasicor Tab 160mgtablet (extended-release)160 mgoralNovartis Pharmaceuticals Canada Inc1981-12-312005-08-02Canada
Slow Trasicor Tab 80mgtablet (extended-release)80 mgoralNovartis Pharmaceuticals Canada Inc1981-12-312005-08-02Canada
Trasicor Tab 20mgtablet20 mgoralNovartis Pharmaceuticals Canada Inc1980-12-311999-08-04Canada
Trasicor Tab 40mgtablet40 mgoralNovartis Pharmaceuticals Canada Inc1980-12-312008-01-22Canada
Trasicor Tab 80mgtablet80 mgoralNovartis Pharmaceuticals Canada Inc1980-12-312009-02-25Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
TrasacorNot Available
TrasicorNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxprenolol hydrochloride
ThumbNot applicableDBSALT001070
Categories
UNII519MXN9YZR
CAS number6452-71-7
WeightAverage: 265.348
Monoisotopic: 265.167793607
Chemical FormulaC15H23NO3
InChI KeyInChIKey=CEMAWMOMDPGJMB-UHFFFAOYSA-N
InChI
InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
IUPAC Name
1-[2-(prop-2-en-1-yloxy)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC=C1OCC=C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
PharmacodynamicsOxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. Oxprenolol is an potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation.
Mechanism of actionLike other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Related Articles
AbsorptionOral bioavailability is 20-70%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life1-2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxprenolol Action PathwayDrug actionSMP00304
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9817
Blood Brain Barrier-0.9759
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6618
P-glycoprotein inhibitor INon-inhibitor0.5567
P-glycoprotein inhibitor IINon-inhibitor0.8945
Renal organic cation transporterNon-inhibitor0.8698
CYP450 2C9 substrateNon-substrate0.8122
CYP450 2D6 substrateNon-substrate0.5424
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9209
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8958
Ames testNon AMES toxic0.9367
CarcinogenicityNon-carcinogens0.9206
BiodegradationNot ready biodegradable0.9593
Rat acute toxicity2.5730 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9351
hERG inhibition (predictor II)Non-inhibitor0.7501
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet (extended-release)oral160 mg
Tablet (extended-release)oral80 mg
Tabletoral20 mg
Tabletoral40 mg
Tabletoral80 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.10HANSCH,C ET AL. (1995)
Caco2 permeability-4.68ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.68 mg/mLALOGPS
logP2.44ALOGPS
logP2.17ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity76 m3·mol-1ChemAxon
Polarizability30.31 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. McDevitt DG: Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J. 1987 Dec;8 Suppl M:9-14. [PubMed:2897304 ]
External Links
ATC CodesC07CA02C07BA02C07AA02
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Oxprenolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Oxprenolol.
AcebutololAcebutolol may increase the hypotensive activities of Oxprenolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Oxprenolol.
AcepromazineAcepromazine may increase the hypotensive activities of Oxprenolol.
AcepromazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Aceprometazine.
AcetohexamideOxprenolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Acetylcholine.
AcetyldigitoxinOxprenolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Oxprenolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Oxprenolol.
adipiplonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with adipiplon.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
AgomelatineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxprenolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Oxprenolol.
AlfuzosinOxprenolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Oxprenolol.
AliskirenOxprenolol may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Oxprenolol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxprenolol.
AlprenololAlprenolol may increase the hypotensive activities of Oxprenolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Oxprenolol.
AmbrisentanOxprenolol may increase the hypotensive activities of Ambrisentan.
AmifostineOxprenolol may increase the hypotensive activities of Amifostine.
AminophyllineOxprenolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Oxprenolol.
AmisulprideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Oxprenolol.
AmobarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Amobarbital.
AmobarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amobarbital.
AmodiaquineThe metabolism of Oxprenolol can be decreased when combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amoxapine.
AmoxapineThe serum concentration of Oxprenolol can be increased when it is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amperozide.
AntipyrineAntipyrine may decrease the antihypertensive activities of Oxprenolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
ApraclonidineApraclonidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
ApremilastApremilast may decrease the antihypertensive activities of Oxprenolol.
ArbutamineOxprenolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Arecoline.
ArformoterolOxprenolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxprenolol.
ArticaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Asenapine.
AtenololAtenolol may increase the hypotensive activities of Oxprenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Azaperone.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Oxprenolol.
AzelastineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineAzelastine may decrease the antihypertensive activities of Oxprenolol.
BaclofenThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Baclofen.
BalsalazideBalsalazide may decrease the antihypertensive activities of Oxprenolol.
BambuterolOxprenolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Barbital.
BarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Oxprenolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Oxprenolol.
BenmoxinBenmoxin may increase the hypotensive activities of Oxprenolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Oxprenolol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Oxprenolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Benzyl alcohol.
BepridilBepridil may increase the hypotensive activities of Oxprenolol.
BetaxololBetaxolol may increase the hypotensive activities of Oxprenolol.
BethanecholThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Oxprenolol.
BimatoprostBimatoprost may increase the hypotensive activities of Oxprenolol.
BisoprololBisoprolol may increase the hypotensive activities of Oxprenolol.
BosentanBosentan may increase the hypotensive activities of Oxprenolol.
BretyliumBretylium may increase the hypotensive activities of Oxprenolol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brexpiprazole.
BrimonidineOxprenolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Oxprenolol.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol.
BromfenacBromfenac may decrease the antihypertensive activities of Oxprenolol.
BromocriptineOxprenolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
BrompheniramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brotizolam.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxprenolol.
BupranololOxprenolol may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Oxprenolol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxprenolol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxprenolol.
ButacaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Oxprenolol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxprenolol.
CabergolineOxprenolol may increase the vasoconstricting activities of Cabergoline.
CandesartanCandesartan may increase the hypotensive activities of Oxprenolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Oxprenolol.
CaptoprilCaptopril may increase the hypotensive activities of Oxprenolol.
CarbacholThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbachol.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxprenolol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Oxprenolol.
CarisoprodolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the hypotensive activities of Oxprenolol.
CarprofenCarprofen may decrease the antihypertensive activities of Oxprenolol.
CarteololCarteolol may increase the hypotensive activities of Oxprenolol.
CarvedilolCarvedilol may increase the hypotensive activities of Oxprenolol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Oxprenolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Oxprenolol.
CeliprololCeliprolol may increase the hypotensive activities of Oxprenolol.
CeliprololOxprenolol may decrease the bronchodilatory activities of Celiprolol.
CetirizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cetirizine.
CevimelineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cevimeline.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxprenolol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxprenolol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Oxprenolol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxprenolol.
ChloroquineChloroquine may decrease the antihypertensive activities of Oxprenolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Oxprenolol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorphenamine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Oxprenolol.
ChlorpromazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorpromazine.
ChlorpropamideOxprenolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxprenolol.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Oxprenolol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorzoxazone.
CilazaprilCilazapril may increase the hypotensive activities of Oxprenolol.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxprenolol.
CitalopramThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clemastine.
ClenbuterolOxprenolol may decrease the bronchodilatory activities of Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clomipramine.
ClomipramineThe serum concentration of Oxprenolol can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clonazepam.
ClonidineClonidine may increase the hypotensive activities of Oxprenolol.
ClonixinClonixin may decrease the antihypertensive activities of Oxprenolol.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxprenolol.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxprenolol.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Oxprenolol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxprenolol.
CoumaphosCoumaphos may increase the bradycardic activities of Oxprenolol.
CryptenamineCryptenamine may increase the hypotensive activities of Oxprenolol.
CyclizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.
CyclothiazideCyclothiazide may increase the hypotensive activities of Oxprenolol.
CyproheptadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyproheptadine.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Oxprenolol.
DantroleneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxprenolol.
DapoxetineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dapoxetine.
DapoxetineThe serum concentration of Oxprenolol can be increased when it is combined with Dapoxetine.
DebrisoquinOxprenolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Oxprenolol.
DemecariumDemecarium may increase the bradycardic activities of Oxprenolol.
deramciclaneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with deramciclane.
DeserpidineOxprenolol may increase the hypotensive activities of Deserpidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxprenolol.
DesipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desipramine.
DeslanosideOxprenolol may increase the bradycardic activities of Deslanoside.
DesloratadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxprenolol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Oxprenolol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxprenolol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Oxprenolol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxprenolol.
DiazoxideDiazoxide may increase the hypotensive activities of Oxprenolol.
DichlorvosDichlorvos may increase the bradycardic activities of Oxprenolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Oxprenolol.
DifenoxinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Difenoxin.
DiflunisalDiflunisal may decrease the antihypertensive activities of Oxprenolol.
DigitoxinOxprenolol may increase the bradycardic activities of Digitoxin.
DigoxinOxprenolol may increase the bradycardic activities of Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxprenolol.
DihydroergotamineOxprenolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Oxprenolol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxprenolol.
DiltiazemDiltiazem may increase the hypotensive activities of Oxprenolol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxprenolol.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxprenolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
DipivefrinOxprenolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Oxprenolol.
DisopyramideDisopyramide may increase the bradycardic activities of Oxprenolol.
DobutamineOxprenolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Oxprenolol.
DoramectinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doramectin.
DorzolamideDorzolamide may increase the hypotensive activities of Oxprenolol.
DoxazosinDoxazosin may increase the hypotensive activities of Oxprenolol.
DoxepinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
DoxylamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Oxprenolol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
DronedaroneDronedarone may increase the bradycardic activities of Oxprenolol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxprenolol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Oxprenolol.
DroxicamDroxicam may decrease the antihypertensive activities of Oxprenolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
DroxidopaOxprenolol may decrease the bronchodilatory activities of Droxidopa.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.
DyphyllineOxprenolol may decrease the bronchodilatory activities of Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Oxprenolol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Oxprenolol is combined with ECGONINE METHYL ESTER.
EchothiophateEchothiophate may increase the bradycardic activities of Oxprenolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Oxprenolol.
EfavirenzThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Efavirenz.
EfonidipineOxprenolol may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Oxprenolol.
EnalaprilatOxprenolol may increase the hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxprenolol.
EntacaponeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Entacapone.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
EphedraOxprenolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Oxprenolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
EpinephrineOxprenolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Oxprenolol.
EpoprostenolEpoprostenol may increase the hypotensive activities of Oxprenolol.
EprosartanEprosartan may increase the hypotensive activities of Oxprenolol.
Ergoloid mesylateOxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineOxprenolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineOxprenolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
EscitalopramThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Oxprenolol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxprenolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Oxprenolol.
EthanolOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Oxprenolol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.
EthosuximideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Oxprenolol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Oxprenolol.
EtidocaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etizolam.
EtodolacEtodolac may decrease the antihypertensive activities of Oxprenolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Oxprenolol.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxprenolol.
EtoperidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etoperidone.
EtoperidoneThe serum concentration of Oxprenolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Oxprenolol.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Oxprenolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Oxprenolol.
exisulindexisulind may decrease the antihypertensive activities of Oxprenolol.
EzogabineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Felbamate.
FelodipineFelodipine may increase the hypotensive activities of Oxprenolol.
FenbufenFenbufen may decrease the antihypertensive activities of Oxprenolol.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Oxprenolol.
FenfluramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fenfluramine.
FenfluramineThe serum concentration of Oxprenolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Oxprenolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Oxprenolol.
FenoterolOxprenolol may decrease the bronchodilatory activities of Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxprenolol.
FenthionFenthion may increase the bradycardic activities of Oxprenolol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.
FexofenadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fexofenadine.
FingolimodOxprenolol may increase the bradycardic activities of Fingolimod.
FlibanserinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flibanserin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxprenolol.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Oxprenolol.
FlunarizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Oxprenolol.
FlunixinFlunixin may decrease the antihypertensive activities of Oxprenolol.
FluoxetineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluoxetine.
FluoxetineThe serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxprenolol.
FluphenazineFluphenazine may increase the hypotensive activities of Oxprenolol.
FluphenazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxprenolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Oxprenolol.
FluspirileneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluvoxamine.
FormoterolOxprenolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Oxprenolol.
FosphenytoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fospropofol.
FurazolidoneFurazolidone may increase the hypotensive activities of Oxprenolol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxprenolol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with gabapentin enacarbil.
GalantamineGalantamine may increase the bradycardic activities of Oxprenolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Oxprenolol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Oxprenolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Oxprenolol.
GlibornurideOxprenolol may increase the hypoglycemic activities of Glibornuride.
GliclazideOxprenolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideOxprenolol may increase the hypoglycemic activities of Glimepiride.
GlipizideOxprenolol may increase the hypoglycemic activities of Glipizide.
GliquidoneOxprenolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideOxprenolol may increase the hypoglycemic activities of Glisoxepide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Oxprenolol.
GlyburideOxprenolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Oxprenolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Oxprenolol.
GuanadrelGuanadrel may increase the hypotensive activities of Oxprenolol.
GuanethidineGuanethidine may increase the hypotensive activities of Oxprenolol.
GuanfacineGuanfacine may increase the hypotensive activities of Oxprenolol.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Oxprenolol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxprenolol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Oxprenolol.
HexamethoniumOxprenolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Hexobarbital.
HexobarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Hexobarbital.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Oxprenolol.
Huperzine AHuperzine A may increase the bradycardic activities of Oxprenolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Oxprenolol.
HydralazineHydralazine may increase the hypotensive activities of Oxprenolol.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Oxprenolol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Oxprenolol.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Oxprenolol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.
HydroxychloroquineThe metabolism of Oxprenolol can be decreased when combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
HydroxyzineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Hydroxyzine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Oxprenolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Oxprenolol.
IcatibantIcatibant may decrease the antihypertensive activities of Oxprenolol.
IloperidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Iloperidone.
IloprostIloprost may increase the hypotensive activities of Oxprenolol.
ImipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Imipramine.
IndacaterolOxprenolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Indalpine.
IndalpineThe serum concentration of Oxprenolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Oxprenolol.
IndenololOxprenolol may increase the hypotensive activities of Indenolol.
IndomethacinIndomethacin may decrease the antihypertensive activities of Oxprenolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Oxprenolol.
IndoraminOxprenolol may increase the hypotensive activities of Indoramin.
Insulin PorkOxprenolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Oxprenolol.
IproniazidIproniazid may increase the hypotensive activities of Oxprenolol.
IrbesartanIrbesartan may increase the hypotensive activities of Oxprenolol.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Oxprenolol.
IsoetarineOxprenolol may decrease the bronchodilatory activities of Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxprenolol.
IsoflurophateIsoflurophate may increase the bradycardic activities of Oxprenolol.
IsoprenalineOxprenolol may decrease the bronchodilatory activities of Isoprenaline.
IsoxicamIsoxicam may decrease the antihypertensive activities of Oxprenolol.
IsradipineIsradipine may increase the hypotensive activities of Oxprenolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Oxprenolol.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxprenolol.
KetazolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketobemidone.
KetoprofenKetoprofen may decrease the antihypertensive activities of Oxprenolol.
KetorolacKetorolac may decrease the antihypertensive activities of Oxprenolol.
LabetalolLabetalol may increase the hypotensive activities of Oxprenolol.
LacidipineOxprenolol may increase the hypotensive activities of Lacidipine.
LamotrigineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lamotrigine.
LatanoprostLatanoprost may increase the hypotensive activities of Oxprenolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Oxprenolol.
LercanidipineLercanidipine may increase the hypotensive activities of Oxprenolol.
LevetiracetamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Oxprenolol.
LevocabastineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Oxprenolol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levomilnacipran.
LevomilnacipranThe serum concentration of Oxprenolol can be increased when it is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxprenolol.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Oxprenolol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxprenolol.
LisinoprilLisinopril may increase the hypotensive activities of Oxprenolol.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Oxprenolol.
LobelineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lobeline.
LofentanilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lofentanil.
LofexidineOxprenolol may increase the hypotensive activities of Lofexidine.
LoratadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxprenolol.
LornoxicamLornoxicam may decrease the antihypertensive activities of Oxprenolol.
LosartanLosartan may increase the hypotensive activities of Oxprenolol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxprenolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Oxprenolol.
Lu AA21004The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lu AA21004.
Lu AA21004The serum concentration of Oxprenolol can be increased when it is combined with Lu AA21004.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Oxprenolol.
LurasidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lurasidone.
MacitentanOxprenolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Oxprenolol.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Magnesium Sulfate.
MalathionMalathion may increase the bradycardic activities of Oxprenolol.
ManidipineOxprenolol may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Maprotiline.
MasoprocolMasoprocol may decrease the antihypertensive activities of Oxprenolol.
MebanazineMebanazine may increase the hypotensive activities of Oxprenolol.
MecamylamineMecamylamine may increase the hypotensive activities of Oxprenolol.
MeclizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Meclizine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Oxprenolol.
MedetomidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Medetomidine.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Oxprenolol.
MefloquineMefloquine may increase the bradycardic activities of Oxprenolol.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Oxprenolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Oxprenolol.
MelperoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Melperone.
MemantineMemantine may increase the bradycardic activities of Oxprenolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxprenolol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.
MesalazineMesalazine may decrease the antihypertensive activities of Oxprenolol.
MesoridazineMesoridazine may increase the hypotensive activities of Oxprenolol.
MesoridazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Mesoridazine.
MetamizoleMetamizole may decrease the antihypertensive activities of Oxprenolol.
MetaxaloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Metaxalone.
MethacholineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methacholine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Oxprenolol.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
MethapyrileneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methocarbamol.
MethohexitalThe serum concentration of Oxprenolol can be decreased when it is combined with Methohexital.
MethohexitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Oxprenolol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxprenolol.
MethsuximideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methsuximide.
MethyldopaMethyldopa may increase the hypotensive activities of Oxprenolol.
Methylene blueMethylene blue may increase the hypotensive activities of Oxprenolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Oxprenolol.
MethylphenobarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Methylphenobarbital.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methylphenobarbital.
MetipranololMetipranolol may increase the hypotensive activities of Oxprenolol.
MetolazoneMetolazone may increase the hypotensive activities of Oxprenolol.
MetoprololMetoprolol may increase the hypotensive activities of Oxprenolol.
MetyrosineOxprenolol may increase the sedative activities of Metyrosine.
MibefradilMibefradil may increase the hypotensive activities of Oxprenolol.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.
MidodrineOxprenolol may increase the bradycardic activities of Midodrine.
MilnacipranThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Milnacipran.
MilnacipranThe serum concentration of Oxprenolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Oxprenolol.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
MinoxidilMinoxidil may increase the hypotensive activities of Oxprenolol.
MirtazapineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxprenolol.
MoclobemideMoclobemide may increase the hypotensive activities of Oxprenolol.
MoexiprilMoexipril may increase the hypotensive activities of Oxprenolol.
MolindoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Molindone.
MolsidomineMolsidomine may increase the hypotensive activities of Oxprenolol.
MoricizineMoricizine may increase the hypotensive activities of Oxprenolol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxprenolol.
MoxonidineOxprenolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Oxprenolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Oxprenolol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.
NabiloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nabilone.
NabumetoneNabumetone may decrease the antihypertensive activities of Oxprenolol.
NadololNadolol may increase the hypotensive activities of Oxprenolol.
NaftifineNaftifine may decrease the antihypertensive activities of Oxprenolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxprenolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
NaproxenNaproxen may decrease the antihypertensive activities of Oxprenolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Oxprenolol.
NebivololOxprenolol may increase the hypotensive activities of Nebivolol.
NeostigmineNeostigmine may increase the bradycardic activities of Oxprenolol.
NepafenacNepafenac may decrease the antihypertensive activities of Oxprenolol.
NialamideNialamide may increase the hypotensive activities of Oxprenolol.
NicardipineNicardipine may increase the hypotensive activities of Oxprenolol.
NicorandilOxprenolol may increase the hypotensive activities of Nicorandil.
NicotineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Oxprenolol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Oxprenolol.
NiguldipineOxprenolol may increase the hypotensive activities of Niguldipine.
NilvadipineOxprenolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Oxprenolol.
NimodipineNimodipine may increase the hypotensive activities of Oxprenolol.
NisoldipineNisoldipine may increase the hypotensive activities of Oxprenolol.
NitrazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nitrazepam.
NitrendipineNitrendipine may increase the hypotensive activities of Oxprenolol.
NitroprussideNitroprusside may increase the hypotensive activities of Oxprenolol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nitrous oxide.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
NorepinephrineOxprenolol may decrease the bronchodilatory activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nortriptyline.
ObinutuzumabOxprenolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Oxprenolol.
OlanzapineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Olanzapine.
OlanzapineThe serum concentration of Oxprenolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Oxprenolol.
OlodaterolOxprenolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Oxprenolol.
OlopatadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Olopatadine.
OlsalazineOlsalazine may decrease the antihypertensive activities of Oxprenolol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Oxprenolol.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxprenolol.
OpiumThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Opium.
OrciprenalineOxprenolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Oxprenolol.
OrphenadrineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxprenolol.
OsanetantThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Osanetant.
OuabainOxprenolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Oxprenolol.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxprenolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Oxprenolol.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Oxprenolol.
ParaldehydeOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Oxprenolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Oxprenolol.
PargylineOxprenolol may increase the hypotensive activities of Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Paroxetine.
ParoxetineThe serum concentration of Oxprenolol can be increased when it is combined with Paroxetine.
PenbutololPenbutolol may increase the hypotensive activities of Oxprenolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.
PentobarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pentobarbital.
PentoliniumPentolinium may increase the hypotensive activities of Oxprenolol.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Oxprenolol.
PerampanelThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perampanel.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
PerindoprilPerindopril may increase the hypotensive activities of Oxprenolol.
PerospironeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Oxprenolol.
PerphenazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxprenolol.
PhenelzinePhenelzine may increase the hypotensive activities of Oxprenolol.
PheniprazinePheniprazine may increase the hypotensive activities of Oxprenolol.
PhenobarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Oxprenolol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenoxyethanol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Oxprenolol.
PhentolaminePhentolamine may increase the hypotensive activities of Oxprenolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Oxprenolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
PhenylpropanolamineOxprenolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenytoin.
PhysostigminePhysostigmine may increase the bradycardic activities of Oxprenolol.
PilocarpineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Oxprenolol.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxprenolol.
PinacidilOxprenolol may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Oxprenolol.
PipamperoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipotiazine.
PirbuterolOxprenolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Oxprenolol.
PirlindolePirlindole may increase the hypotensive activities of Oxprenolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Oxprenolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Oxprenolol.
PizotifenThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pizotifen.
PolythiazidePolythiazide may increase the hypotensive activities of Oxprenolol.
PomalidomideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.
PramipexoleOxprenolol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam.
PrazosinPrazosin may increase the hypotensive activities of Oxprenolol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxprenolol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Oxprenolol.
PrimaquineThe metabolism of Oxprenolol can be decreased when combined with Primaquine.
PrimidoneThe serum concentration of Oxprenolol can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxprenolol.
ProcaterolOxprenolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Oxprenolol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Prochlorperazine.
PromazinePromazine may increase the hypotensive activities of Oxprenolol.
PromazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Oxprenolol.
PromethazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Promethazine.
PropacetamolPropacetamol may decrease the antihypertensive activities of Oxprenolol.
PropafenoneThe serum concentration of Oxprenolol can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxprenolol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.
PropoxycaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Propoxycaine.
PropranololPropranolol may increase the hypotensive activities of Oxprenolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Oxprenolol is combined with PSD502.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
PTC299PTC299 may decrease the antihypertensive activities of Oxprenolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Oxprenolol.
QuazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxprenolol.
QuinaprilQuinapril may increase the hypotensive activities of Oxprenolol.
QuinineQuinine may increase the hypotensive activities of Oxprenolol.
RamelteonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ramelteon.
RamiprilRamipril may increase the hypotensive activities of Oxprenolol.
RasagilineRasagiline may increase the hypotensive activities of Oxprenolol.
RegorafenibRegorafenib may increase the bradycardic activities of Oxprenolol.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxprenolol.
RemikirenRemikiren may increase the hypotensive activities of Oxprenolol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol.
RescinnamineOxprenolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Oxprenolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Oxprenolol.
RiociguatOxprenolol may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxprenolol.
RitodrineOxprenolol may decrease the bronchodilatory activities of Ritodrine.
RituximabOxprenolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Oxprenolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Oxprenolol.
RomifidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Romifidine.
RopiniroleOxprenolol may increase the sedative activities of Ropinirole.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol.
RotigotineOxprenolol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxprenolol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Oxprenolol is combined with S-Ethylisothiourea.
SafrazineSafrazine may increase the hypotensive activities of Oxprenolol.
SalbutamolOxprenolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Oxprenolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Oxprenolol.
SalmeterolOxprenolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Oxprenolol.
SaprisartanSaprisartan may increase the hypotensive activities of Oxprenolol.
ScopolamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Scopolamine.
SecobarbitalThe serum concentration of Oxprenolol can be decreased when it is combined with Secobarbital.
SecobarbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Oxprenolol.
SelexipagOxprenolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Oxprenolol.
SertindoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertraline.
SertralineThe serum concentration of Oxprenolol can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxprenolol.
SildenafilSildenafil may increase the antihypertensive activities of Oxprenolol.
SilodosinOxprenolol may increase the orthostatic hypotensive activities of Silodosin.
SitaxentanOxprenolol may increase the hypotensive activities of Sitaxentan.
Sodium oxybateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sodium oxybate.
SpiraprilSpirapril may increase the hypotensive activities of Oxprenolol.
SRT501SRT501 may decrease the antihypertensive activities of Oxprenolol.
StiripentolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Oxprenolol.
SulindacSulindac may decrease the antihypertensive activities of Oxprenolol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxprenolol.
SuprofenSuprofen may decrease the antihypertensive activities of Oxprenolol.
SuvorexantThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Suvorexant.
TacrineTacrine may increase the bradycardic activities of Oxprenolol.
TadalafilTadalafil may increase the antihypertensive activities of Oxprenolol.
TamsulosinOxprenolol may increase the orthostatic hypotensive activities of Tamsulosin.
TapentadolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tasimelteon.
TelmisartanTelmisartan may increase the hypotensive activities of Oxprenolol.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxprenolol.
TemocaprilOxprenolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Oxprenolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Oxprenolol.
TerazosinOxprenolol may increase the orthostatic hypotensive activities of Terazosin.
TerbutalineOxprenolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Oxprenolol.
TerlipressinOxprenolol may increase the hypotensive activities of Terlipressin.
TetrabenazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrodotoxin.
ThalidomideOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxprenolol.
TheophyllineOxprenolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThe serum concentration of Oxprenolol can be decreased when it is combined with Thiamylal.
ThiamylalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Oxprenolol.
ThiopentalThe serum concentration of Oxprenolol can be decreased when it is combined with Thiopental.
ThiopentalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Oxprenolol.
ThioridazineThioridazine may increase the hypotensive activities of Oxprenolol.
ThiothixeneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiagabine.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Oxprenolol.
TiboloneOxprenolol may increase the hypotensive activities of Tibolone.
TicrynafenOxprenolol may increase the hypotensive activities of Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiletamine.
TimololTimolol may increase the hypotensive activities of Oxprenolol.
TizanidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tizanidine.
TolazamideOxprenolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Oxprenolol.
TolbutamideOxprenolol may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tolcapone.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Oxprenolol.
TolmetinTolmetin may decrease the antihypertensive activities of Oxprenolol.
ToloxatoneToloxatone may increase the hypotensive activities of Oxprenolol.
TopiramateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Oxprenolol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxprenolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Oxprenolol.
TranilastTranilast may decrease the antihypertensive activities of Oxprenolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Oxprenolol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Oxprenolol.
TranylcypromineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tranylcypromine.
TravoprostTravoprost may increase the hypotensive activities of Oxprenolol.
TrazodoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trazodone.
TrazodoneThe serum concentration of Oxprenolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Oxprenolol.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxprenolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Oxprenolol.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Oxprenolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Oxprenolol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Oxprenolol.
TriflupromazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triflupromazine.
TrimazosinOxprenolol may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Oxprenolol.
TrimipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triprolidine.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Oxprenolol.
TubocurarineTubocurarine may increase the bradycardic activities of Oxprenolol.
UdenafilUdenafil may increase the antihypertensive activities of Oxprenolol.
UnoprostoneOxprenolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Oxprenolol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxprenolol.
ValsartanValsartan may increase the hypotensive activities of Oxprenolol.
VardenafilVardenafil may increase the antihypertensive activities of Oxprenolol.
VareniclineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Varenicline.
VigabatrinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vigabatrin.
VilanterolOxprenolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vilazodone.
VilazodoneThe serum concentration of Oxprenolol can be increased when it is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vortioxetine.
VortioxetineThe serum concentration of Oxprenolol can be increased when it is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Xylazine.
XylometazolineOxprenolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Oxprenolol.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxprenolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Oxprenolol.
ZiconotideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ziconotide.
ZileutonZileuton may decrease the antihypertensive activities of Oxprenolol.
ZimelidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zimelidine.
ZimelidineThe serum concentration of Oxprenolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxprenolol.
ZolazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxprenolol.
ZomepiracZomepirac may decrease the antihypertensive activities of Oxprenolol.
ZonisamideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Oxprenolol.
ZotepineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Campbell CA, Parratt JR, Kane KA, Bullock G: Effects of prolonged administration of oxprenolol on severity of ischaemic arrhythmias, enzyme leakage, infarct size, and intracellular cardiac muscle action potentials. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):369-77. [PubMed:6202960 ]
  4. Lemmer B: [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]. Herz. 1982 Jun;7(3):168-78. [PubMed:6124492 ]
  5. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sekut L, Champion BR, Page K, Menius JA Jr, Connolly KM: Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol. 1995 Mar;99(3):461-6. [PubMed:7882570 ]
  4. Fujita H, Tanaka J, Maeda N, Sakanaka M: Adrenergic agonists suppress the proliferation of microglia through beta 2-adrenergic receptor. Neurosci Lett. 1998 Feb 6;242(1):37-40. [PubMed:9509999 ]
  5. Prinz M, Hausler KG, Kettenmann H, Hanisch U: beta-adrenergic receptor stimulation selectively inhibits IL-12p40 release in microglia. Brain Res. 2001 Apr 27;899(1-2):264-70. [PubMed:11311890 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 08:53 / Updated on August 17, 2016 12:23